Trevena Announces Positive Results from Phase 2b Study of TRV130 in Acute Postoperative Pain
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Dollar pushes higher, yen sinks to 40-year low
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
Trevena (TRVN) Trades Near Day's High; Up 60%
September 1, 2015 10:48 AM EDTTrevena (NASDAQ: TRVN) is adding to early gains bolstered by positive analyst commentary and an upgrade at Barlclays. Shares are now up 62% to $9.71 and just off the day's high of $10.
After the close, Trevena... More
Barclays Upgrades Trevena (TRVN) to Overweight
September 1, 2015 10:44 AM EDTBarclays upgraded Trevena (NASDAQ: TRVN) from Equalweight to Overweight with a price target of $18.00.
For an analyst ratings summary and ratings history on Trevena click here. For more ratings news on Trevena click here.
Shares of Trevena closed at $6.00 yesterday.
... MoreRoth Capital Reiterates Buy on Trevena (TRVN) Following TRV130’s Phase 2b Results
September 1, 2015 9:41 AM EDTRoth Capital reiterated a Buy rating and $14.50 price target on Trevena (NASDAQ: TRVN) as the company announced that TRV130 met primary and secondary endpoints in four arm Phase 2b. TRV130 is a new chemical entity, a biased mu opioid receptor ligand... More
Needham & Company Reiterates Buy on Trevena (TRVN) Following Positive TRV130 Results
September 1, 2015 8:45 AM EDTNeedham & Company reiterated a Buy rating and $14.00 price target on Trevena (NASDAQ: TRVN) following positive results from phase 2 TRV130 Soft Tissue Surgery Trial. Management did not provide guidance on Phase 3 trial design.
Analyst Alan Carr commented, "Trevena announced results from its Phase 2b... More
Trevena (TRVN) PT Bumped to $14 at Cowen as TRV130 Shows Strong Safety And Efficacy Profile
September 1, 2015 7:32 AM EDTCowen analyst Ritu Baral reiterated an Outperform rating and bumped her price target on Trevena (NASDAQ: TRVN) to $14.00 (from $13.00) based on increased conviction around TRV130, which yesterday showed more positive Ph2b data (stat sig vs. PBO) in postoperative soft tissue pain... More
Trevena (TRVN) PT Raised to $20 at Wedbush
September 1, 2015 6:44 AM EDTWedbush analyst Heather Behanna reiterated an Outperform rating and boosted her price target on Trevena (NASDAQ: TRVN) to $20.00 (from $15.00) as TRV130 shines in real world setting compared to morphine and placebo in its Phase II abdominoplasty study. The study investigated TRV130 via patient controlled... More
Trevena (TRVN) Announces TRV130 Phase 2b Met Primary Endpoint in Acute Postoperative Pain
August 31, 2015 4:02 PM EDTTrevena (NASDAQ: TRVN) announced positive data from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of TRV130 in moderate to severe acute postoperative pain after abdominoplasty surgery. The study achieved its primary endpoint of statistically greater pain reduction than placebo over 24 hours. In addition, TRV130 was superior to morphine in pre-specified secondary measures, exhibiting significantly reduced nausea, vomiting, and hypoventilation... More
